– UK, Cambridge – Cambridge Cognition Holdings plc (LON: COG), which develops and markets digital solutions to assess brain health, today announced that Richard Bungay will join the Board as a Non-Executive Director with immediate effect.
About Cambridge Cognition
Mr. Bungay has over 25 years’ experience in corporate roles with R&D-based companies within the biotechnology and pharmaceutical sector, including as CFO of both public and private companies, with a particular focus on financing, investor relations and business development. Richard is currently CFO of Diurnal Group plc, the AIM-quoted speciality pharmaceutical company targeting patient needs in chronic endocrine diseases.
Prior to that, Richard was CFO and CEO of Mereo BioPharma Group plc, a biopharmaceutical company focused on rare and speciality diseases. Richard’s other experience includes being CFO of Glide Technologies, a device and development company focused on solid dose formulations of therapeutics and vaccines, and CFO of Verona Pharma plc, a drug development company focused on first-in-class medicines to treat respiratory diseases.
Richard qualified as a Chartered Accountant with Deloitte in 1993.
About Cambridge Cognition
Cambridge Cognition is a neuroscience technology company developing digital health products to better understand, detect and treat conditions affecting brain health. The Company’s software products assess cognitive health in patients worldwide to improve clinical trial outcomes, identify and stratify patients early and improve global efficiency in the pharmaceutical and healthcare industries.
For more information: https://www.cambridgecognition.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
